Life Sciences

DOJ withdraws motion against Ranbaxy

Pharma Compliance Alert, October 15, 2008

Generic drug maker Ranbaxy agreed to turn over audits to the Department of Justice (DOJ), and in response the DOJ withdrew a motion against the company. Ranbaxy initially claimed the audits, which were conducted by Parexel, were privileged.

Post a Comment

Name:

 

E-mail:

 

Please enter your comment below:

   

Please enter the text below:

   
   

Most Popular